CollPlant Biotechnologies Ltd.
CLGN
Rank in Stocks
#29334
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine... CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages in the three-dimensional (3D) bioprinting of tissues and organs, alongside developing solutions for medical aesthetics. All of CollPlant's offerings are underpinned by its proprietary plant-based genetic engineering technology, which facilitates the production of recombinant type I human collagen. Its diverse product portfolio encompasses BioInks engineered for 3D tissue and organ fabrication; dermal and soft tissue fillers designed to diminish wrinkles; and innovative breast implants, both 3D bioprinted and injectable, aimed at promoting breast tissue regeneration. CollPlant also provides a 3D bioprinted regenerative soft tissue matrix. Specialized products include VergenixSTR, a soft tissue repair matrix targeting tendinopathy, and VergenixFG, an advanced wound care treatment for deep surgical incisions and persistent wounds such as diabetic, venous, and pressure ulcers, burns, and bedsores. The company maintains strategic collaboration agreements with numerous partners, including 3D Systems Corporation, CellInk (a BICO Group company), the Advanced Regenerative Manufacturing Institute, the RegenMed Development Organization, Israel's Technion Institute of Technology, AbbVie, and STEMCELL. Established in Rehovot, Israel, in 2004, the company was formerly known as CollPlant Holdings Ltd. before adopting its current name in June 2019.
Share Price
$4.29
Last synced: 2026-11-09
Market Cap
$8.11M
Change (1 day)
8.06%
Change (1 year)
126.98%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade CollPlant Biotechnologies Ltd. (CLGN)
Category
Healthcare
EPS for CollPlant Biotechnologies Ltd. (CLGN)
EPS as of June 2026 TTM: $-9.39
According to CollPlant Biotechnologies Ltd.'s latest financial reports, its current EPS (TTM) is $-9.39. At the end of 2025 the company had an EPS of $-9.40, an increase over its 2024 EPS of $-14.50.
EPS history for CollPlant Biotechnologies Ltd. from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-9.39 | -0.11% |
| 2025 | $-9.40 | -35.17% |
| 2024 | $-14.50 | 133.87% |
| 2023 | $-6.20 | -59.21% |
| 2022 | $-15.20 | -3,807.32% |
| 2021 | $0.41 | -104.88% |
| 2020 | $-8.40 | -71.53% |
| 2019 | $-29.50 | 106.29% |
| 2018 | $-14.30 | -37.00% |
| 2017 | $-22.70 | -36.94% |
| 2016 | $-36.00 | 27.21% |
| 2015 | $-28.30 | 36.06% |
| 2014 | $-20.80 | -54.39% |
| 2013 | $-45.60 | -15.08% |
| 2012 | $-53.70 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -266.77% |
US
|
|
| $-7.07 | -24.71% |
US
|
|
| $-5.29 | -43.66% |
AU
|
|
| $12.88 | -237.17% |
BE
|
|
| $21.56 | -329.61% |
NL
|
Questions about CollPlant Biotechnologies Ltd.'s earnings per share (EPS)
What is CollPlant Biotechnologies Ltd.'s earnings per share (EPS)?
CollPlant Biotechnologies Ltd.'s earnings per share (EPS) over the last twelve months is $-9.39, as of Jun 2026.
What was CollPlant Biotechnologies Ltd.'s earnings per share (EPS) in 2025?
In 2025, CollPlant Biotechnologies Ltd.'s earnings per share (EPS) was $-9.40, compared with $-14.50 in 2024.
How has CollPlant Biotechnologies Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, CollPlant Biotechnologies Ltd.'s earnings per share (EPS) was highest in 2021 ($0.41) and lowest in 2022 ($-15.20).
How does CollPlant Biotechnologies Ltd.'s earnings per share (EPS) compare with similar companies?
CollPlant Biotechnologies Ltd.'s earnings per share (EPS) ($-9.39) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.